Transfusion guided by quality of life for MDS or AML
Part of Blood & lymphatic, Cancer clinical trials.
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have MDS or AML that is not being treated with a goal of cure (you are on palliative care)
- You have anemia (low red blood cells) with hemoglobin levels 8 g/dL or lower (or 9 g/dL if you have heart disease)
- You need more than 2 red blood cell transfusions every 8 weeks
- You do not have a vitamin or iron deficiency that would cause anemia
- You don't have an active uncontrolled infection, severe heart disease, or another cancer (except for some skin or cervical and breast cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This trial tests an experimental drug, HS-20106, to see if it can improve low red blood cell counts (anemia) for people with a certain type of bone marrow disorder called myelodysplastic syndromes (MDS), which is not high risk. It might be an option if you have not received certain prior treatments.
This trial tests whether giving more or fewer red blood cell transfusions is better for adult patients on ECMO (a machine that helps your heart and lungs work). The goal is to find the best transfusion approach to improve outcomes.
This study looks at how well transfusions work and how they affect quality of life in people with lower-risk MDS who need regular blood transfusions. The goal is to find what predicts a good transfusion response and to improve care.
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.